logo

$5 And Under

Share SHARE

HTG Molecular Diagnostics (HTGM) reported a fourth quarter net loss of $0.76 per share after the bell Thursday, compared to the loss of $0.83 per share last year. Revenue came in at $1.5 million, up from $1.2 million last year. HTG Molecular Diagnostics gapped open higher Friday and has risen sharply...

Xenon Pharmaceuticals Inc. (XENE) announced Friday morning that its Phase 2 study of XEN801 in patients with moderate to severe acne did not demonstrate a statistically significant difference from vehicle placebo in its primary endpoint. Xenon Pharmaceuticals has gapped open dramatically lower this...

HTG Molecular Diagnostics (HTGM) announced after the bell Wednesday that it has obtained CE marking in the European Union for its HTG EdgeSeq ALKPlus Assay EU. The stock is now up 1.11 on 124K shares. HTG Molecular Diagnostics traded in a narrow range throughout Wednesday's session and closed up by 0.17 at $2.14.

Interpace Diagnostics Group (IDXG) gapped up slightly Wednesday and has risen sharply in early trade. Shares are now up 0.81 at $3.26 on above average volume. Interpace Diagnostics has jumped to a 1-month high and has re-crossed its 200-day moving average.

Cerulean Pharma Inc. (CERU) announced Monday morning that it has entered into a definitive stock purchase agreement with privately-held Daré Bioscience through which equityholders of Daré Bioscience will become the majority owners of Cerulean. Cerulean Pharma gapped open sharply lower Monday, but...

Aevi Genomic Medicine (GNMX) announced Monday morning that its SAGA trial of AEVI-001 in adolescents with mGluR mutation positive ADHD did not meet the primary endpoint of reduction on the ADHD rating scale compared to placebo. Aevi Genomic Medicine gapped open dramatically lower Monday, but moved...

Cerulean Pharma Inc. (CERU) announced Monday morning that it has entered into a definitive stock purchase agreement with privately-held Daré Bioscience through which equityholders of Daré Bioscience will become the majority owners of Cerulean. Cerulean Pharma has gapped open sharply lower this morning...

Aevi Genomic Medicine (GNMX) announced Monday morning that its SAGA trial of AEVI-001 in adolescents with mGluR mutation positive ADHD did not meet the primary endpoint of reduction on the ADHD rating scale compared to placebo. Aevi Genomic Medicine gapped open dramatically lower Monday morning and...

Pulmatrix Inc. (PULM) has spiked sharply to the upside in the last 15 minutes and is currently higher by 0.80 at $3.14. Pulmatrix is attempting to rebound following a 3-week decline.

Caladrius Biosciences Inc. (CLBS) reported a fourth quarter loss of $0.73 Friday morning, compared to the loss of $5.92 per share last year. Caladrius Biosciences gapped open sharply higher Friday, but has pared its gains in early trade. Shares are now up 1.30 at $6.40 on the highest volume of the...

Ruby Tuesday Inc. (RT) has announced it is exploring strategic alternatives, including a potential sale of the company, as the company continues to struggle with lower traffic at its casual restaurants. Ruby Tuesday gapped open higher Tuesday and climbed during the first 45 minutes of trade. The stock...

Tracon Pharmaceuticals Inc. (TCON) announced after the bell Tuesday that it has entered into a common stock purchase agreement with Aspire Capital Fund for up to $21.0 million. The stock is now up 0.45 on 4K shares. Tracon Pharmaceuticals dipped in early trade Tuesday and ended the session with a...

Dragonwave Inc. (DRWI) announced after the bell Monday that it has signed a new Master Sales and Services Agreement with Ingram Micro Australia. Dragonwave gapped up at the open Tuesday and has risen sharply in early trade. The stock is now up 1.19 at $2.34 on above average volume and has leaped...

Aralez Pharmaceuticals (ARLZ) reported a fourth quarter GAAP loss of $0.48 per share Monday morning, compared to the loss of $0.40 per share last year. Aralez Pharmaceuticals gapped open lower Monday and declined until mid-morning. The stock was range-bound for the rest of the session and closed...

Cerulean Pharma Inc. (CERU) gapped open higher Monday and has risen sharply in early trade on above average volume. The stock is now up 0.80 at $2.32. Cerulean Pharma has broken out of a 5-week trading range and has set nearly a 7-month high.

Follow RTT